Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Belgium

Next Previous
Trial Profile

BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Belgium

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease; Myocardial infarction; Thrombosis; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms BIOFLOW-III
  • Sponsors BIOTRONIK

Most Recent Events

  • 26 Sep 2017 Status changed from active, no longer recruiting to completed.
  • 11 Apr 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
  • 08 Sep 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top